Symbols / KLRS Stock $4.83 +2.77% Kalaris Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
KLRS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Andrew Oxtoby
Exch · Country NGM · United States
Market Cap 114.92M
Enterprise Value 17.37M
Income -44.10M
Sales —
FCF (ttm) —
Book/sh 3.44
Cash/sh 4.10
Employees 20
Insider 10d —
IPO Jul 30, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.06
PEG —
P/S —
P/B 1.40
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 12.03
Current Ratio 12.19
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.78
EPS next Y -1.58
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-05-12
ROA -27.97%
ROE -66.60%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 23.79M
Shs Float 6.57M
Insider Own 9.90%
Instit Own 78.36%
Short Float 10.71%
Short Ratio 9.20
Short Interest 805.75K
52W High 11.88
vs 52W High -59.34%
52W Low 2.14
vs 52W Low 125.70%
Beta —
Impl. Vol. —
Rel Volume 0.69
Avg Volume 77.34K
Volume 53.20K
Target (mean) $18.75
Tgt Median $19.50
Tgt Low $7.00
Tgt High $25.00
# Analysts 8
Recom Strong_buy
Prev Close $4.70
Price $4.83
Change 2.77%
About

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$18.75
Mean price target
2. Current target
$4.83
Latest analyst target
3. DCF / Fair value
$18.75
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$4.83
Low
$7.00
High
$25.00
Mean
$18.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-14 init Wedbush — → Outperform $17
2026-05-13 main Citizens Market Outperform → Market Outperform $25
2026-04-16 init Morgan Stanley — → Overweight $14
2025-12-23 init Chardan Capital — → Buy $19
2025-11-03 init Citizens — → Market Outperform $20
2025-09-03 init Raymond James — → Strong Buy $23
2025-04-08 init William Blair — → Outperform —
News
RSS: Latest KLRS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 HAGEN BRETT R. Officer — 1,915 $6.72 $12,869
2025-12-22 AKKARAJU SRINIVAS Director and Beneficial Owner of more than 10% of a Class of Security — 1,500,000 $10.00 $15,000,000
2025-12-18 AKKARAJU SRINIVAS Director and Beneficial Owner of more than 10% of a Class of Security — 479,847 $10.42 $5,000,006
2025-03-26 HAGEN BRETT R. Officer — 907 $8.97 $8,135
2025-03-18 PATEL SAMIRBHAI CHANDRAKANTH M.D. Director — 352,800 $0.00 $0
2025-03-18 FEINSOD MATTHEW Officer — 4,030 $0.00 $0
2025-03-18 FERRARA NAPOLEONE Director — 504,000 $0.00 $0
2025-03-18 AKKARAJU SRINIVAS Director and Beneficial Owner of more than 10% of a Class of Security — 11,444,503 $0.00 $0
2025-02-21 SINHA VIKAS Chief Executive Officer — 303 $10.08 $3,053
2025-02-21 MILLER EDWARD General Counsel — 106 $10.08 $1,068
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
46.15
-10.79%
51.73
+284.22%
13.46
-3.87%
14.01
Research And Development
30.75
-31.72%
45.04
+284.74%
11.71
-0.48%
11.76
Selling General And Administration
15.40
+130.18%
6.69
+280.76%
1.76
-21.67%
2.24
General And Administrative Expense
15.40
+130.18%
6.69
+280.76%
1.76
-21.67%
2.24
Other Gand A
15.40
+130.18%
6.69
+280.76%
1.76
-21.67%
2.24
Total Expenses
46.15
-10.79%
51.73
+284.22%
13.46
-3.87%
14.01
Operating Income
-46.15
+10.79%
-51.73
-284.22%
-13.46
+3.87%
-14.01
Total Operating Income As Reported
-46.15
+10.79%
-51.73
-284.22%
-13.46
+3.87%
-14.01
EBITDA
-41.98
+36.84%
-66.47
-374.35%
-14.01
+8.12%
-15.25
Normalized EBITDA
-43.02
-40.92%
-30.53
-113.23%
-14.32
+9.33%
-15.79
Reconciled Depreciation
0.01
0.00
—
—
EBIT
-41.99
+36.82%
-66.47
-374.35%
-14.01
+8.12%
-15.25
Total Unusual Items
1.04
+102.90%
-35.93
-11804.89%
0.31
-43.46%
0.54
Total Unusual Items Excluding Goodwill
1.04
+102.90%
-35.93
-11804.89%
0.31
-43.46%
0.54
Special Income Charges
-0.19
+99.51%
-38.02
—
—
Other Special Charges
0.19
-99.51%
38.02
—
—
Net Income
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Pretax Income
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Net Non Operating Interest Income Expense
-1.44
+46.58%
-2.70
-293.16%
-0.69
-192.34%
-0.23
Interest Expense Non Operating
1.44
-46.58%
2.70
+293.16%
0.69
+192.34%
0.23
Net Interest Income
-1.44
+46.58%
-2.70
-293.16%
-0.69
-192.34%
-0.23
Interest Expense
1.44
-46.58%
2.70
+293.16%
0.69
+192.34%
0.23
Other Income Expense
4.16
+128.21%
-14.73
-2588.69%
-0.55
+55.95%
-1.24
Other Non Operating Income Expenses
3.11
-85.31%
21.20
+2579.53%
-0.85
+52.15%
-1.79
Gain On Sale Of Security
1.23
-41.03%
2.08
+578.83%
0.31
-43.46%
0.54
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Net Income From Continuing Operation Net Minority Interest
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Net Income From Continuing And Discontinued Operation
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Net Income Continuous Operations
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Normalized Income
-44.48
-33.85%
-33.23
-121.46%
-15.01
+6.38%
-16.03
Net Income Common Stockholders
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Diluted EPS
-2.85
+23.07%
-3.70
+66.53%
-11.05
+5.08%
-11.64
Basic EPS
-2.85
+23.07%
-3.70
+66.53%
-11.05
+5.08%
-11.64
Basic Average Shares
15.27
-18.36%
18.70
+1305.93%
1.33
+0.00%
1.33
Diluted Average Shares
15.27
-18.36%
18.70
+1305.93%
1.33
+0.00%
1.33
Diluted NI Availto Com Stockholders
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
121.74
+1875.59%
6.16
+84.88%
3.33
-14.52%
3.90
Current Assets
118.81
+4459.06%
2.61
-21.81%
3.33
-14.52%
3.90
Cash Cash Equivalents And Short Term Investments
117.98
+7098.41%
1.64
-48.28%
3.17
+3.60%
3.06
Cash And Cash Equivalents
98.05
+5882.55%
1.64
-48.28%
3.17
+3.60%
3.06
Other Short Term Investments
19.93
0.00
—
—
Prepaid Assets
0.75
-22.54%
0.97
+557.82%
0.15
-82.44%
0.84
Other Current Assets
0.08
—
0.02
+466.67%
0.00
Total Non Current Assets
2.93
-17.69%
3.56
0.00
0.00
Net PPE
1.48
0.00
—
—
Gross PPE
1.48
0.00
—
—
Other Properties
1.48
—
—
—
Non Current Deferred Assets
0.00
-100.00%
3.15
—
—
Other Non Current Assets
1.45
+254.15%
0.41
—
—
Total Liabilities Net Minority Interest
42.92
-58.24%
102.78
+112.57%
48.35
+41.49%
34.17
Current Liabilities
9.71
-60.68%
24.70
+526.66%
3.94
-30.73%
5.69
Payables And Accrued Expenses
7.80
+146.43%
3.16
-7.00%
3.40
-36.94%
5.39
Payables
1.28
-17.88%
1.56
-34.32%
2.38
-14.57%
2.78
Accounts Payable
1.28
-17.88%
1.56
-33.95%
2.36
-14.39%
2.76
Current Accrued Expenses
6.52
+306.23%
1.60
+56.18%
1.03
-60.73%
2.62
Pensionand Other Post Retirement Benefit Plans Current
1.60
+170.90%
0.59
+26.82%
0.47
+80.62%
0.26
Current Debt And Capital Lease Obligation
0.32
-98.38%
19.54
—
—
Current Debt
—
19.54
—
—
Other Current Borrowings
—
19.54
—
—
Current Capital Lease Obligation
0.32
0.00
—
—
Other Current Liabilities
—
1.41
+1801.35%
0.07
+94.74%
0.04
Total Non Current Liabilities Net Minority Interest
33.21
-57.47%
78.08
+75.81%
44.41
+55.93%
28.48
Long Term Debt And Capital Lease Obligation
1.13
0.00
—
3.25
Long Term Debt
—
—
—
3.25
Long Term Capital Lease Obligation
1.13
0.00
—
—
Other Non Current Liabilities
32.08
+0.00%
32.08
—
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
46.00
+3.58%
44.41
+77.88%
24.96
Stockholders Equity
78.81
+181.57%
-96.62
-114.62%
-45.02
-48.71%
-30.27
Common Stock Equity
78.81
+181.57%
-96.62
-114.62%
-45.02
-48.71%
-30.27
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
22.90
+22.46%
18.70
+0.00%
18.70
+0.00%
18.70
Ordinary Shares Number
22.90
+22.46%
18.70
+0.00%
18.70
+0.00%
18.70
Additional Paid In Capital
238.81
+1097.32%
19.95
+739.08%
2.38
-1.90%
2.42
Retained Earnings
-160.00
-37.27%
-116.56
-145.94%
-47.39
-44.96%
-32.70
Gains Losses Not Affecting Retained Earnings
0.01
0.00
—
—
Total Equity Gross Minority Interest
78.81
+181.57%
-96.62
-114.62%
-45.02
-48.71%
-30.27
Total Capitalization
78.81
+181.57%
-96.62
-114.62%
-45.02
-66.61%
-27.02
Working Capital
109.09
+593.71%
-22.10
-3528.41%
-0.61
+66.02%
-1.79
Invested Capital
78.81
+202.26%
-77.08
-71.21%
-45.02
-66.61%
-27.02
Total Debt
1.45
-92.59%
19.54
—
3.25
Net Debt
—
17.90
—
0.19
Capital Lease Obligations
1.45
0.00
—
—
Net Tangible Assets
78.81
+181.57%
-96.62
-114.62%
-45.02
-48.71%
-30.27
Tangible Book Value
78.81
+181.57%
-96.62
-114.62%
-45.02
-48.71%
-30.27
Derivative Product Liabilities
—
—
0.00
-100.00%
0.26
Dueto Related Parties Current
—
—
0.01
-38.10%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-38.37
-85.63%
-20.67
-46.26%
-14.13
-44.51%
-9.78
Cash Flow From Continuing Operating Activities
-38.37
-85.63%
-20.67
-46.26%
-14.13
-44.51%
-9.78
Net Income From Continuing Operations
-43.44
+37.20%
-69.17
-370.56%
-14.70
+5.08%
-15.48
Depreciation Amortization Depletion
0.01
0.00
—
—
Depreciation
0.01
0.00
—
—
Depreciation And Amortization
0.01
0.00
—
—
Other Non Cash Items
0.73
-94.69%
13.79
+658.69%
1.82
-29.62%
2.58
Stock Based Compensation
1.94
+116.31%
0.90
+504.73%
0.15
-45.39%
0.27
Operating Gains Losses
-1.04
-102.90%
35.93
+11804.89%
-0.31
+43.46%
-0.54
Gain Loss On Investment Securities
-1.23
+41.03%
-2.08
-578.83%
-0.31
+43.46%
-0.54
Change In Working Capital
3.43
+261.41%
-2.12
-94.60%
-1.09
-132.16%
3.40
Change In Prepaid Assets
1.81
+325.40%
-0.80
-218.79%
0.68
+216.15%
-0.58
Change In Payables And Accrued Expense
2.06
+325.44%
-0.91
+48.42%
-1.77
-144.46%
3.98
Change In Accrued Expense
2.14
+1764.35%
0.12
+108.42%
-1.37
-163.59%
2.15
Change In Payable
-0.09
+91.43%
-1.03
-155.47%
-0.40
-121.98%
1.83
Change In Account Payable
-0.09
+91.43%
-1.03
-155.47%
-0.40
-121.98%
1.83
Change In Other Current Assets
-0.35
+13.41%
-0.41
—
—
Change In Other Current Liabilities
-0.08
0.00
—
—
Investing Cash Flow
-19.72
0.00
—
—
Cash Flow From Continuing Investing Activities
-19.72
0.00
—
—
Net PPE Purchase And Sale
-0.20
0.00
—
—
Purchase Of PPE
-0.20
0.00
—
—
Capital Expenditure
-0.20
—
—
—
Net Investment Purchase And Sale
-19.52
0.00
—
—
Purchase Of Investment
-34.52
0.00
—
—
Sale Of Investment
15.00
0.00
—
—
Financing Cash Flow
155.01
+709.86%
19.14
+34.39%
14.24
+11.44%
12.78
Cash Flow From Continuing Financing Activities
155.01
+709.86%
19.14
+34.39%
14.24
+11.44%
12.78
Net Issuance Payments Of Debt
7.50
-62.44%
19.97
+232.77%
6.00
+39.53%
4.30
Issuance Of Debt
7.50
-62.44%
19.97
+232.77%
6.00
+39.53%
4.30
Long Term Debt Issuance
7.50
-62.44%
19.97
+232.77%
6.00
+39.53%
4.30
Net Long Term Debt Issuance
7.50
-62.44%
19.97
+232.77%
6.00
+39.53%
4.30
Net Common Stock Issuance
42.00
0.00
—
—
Proceeds From Stock Option Exercised
8.00
+266566.67%
0.00
0.00
-100.00%
0.01
Net Other Financing Charges
97.51
+4129.21%
-2.42
-261.33%
1.50
—
Changes In Cash
96.91
+6434.25%
-1.53
-1490.91%
0.11
-96.33%
3.00
Beginning Cash Position
1.64
-48.28%
3.17
+3.60%
3.06
+5174.14%
0.06
End Cash Position
98.55
+5913.00%
1.64
-48.28%
3.17
+3.60%
3.06
Free Cash Flow
-38.57
-86.60%
-20.67
-46.26%
-14.13
-44.51%
-9.78
Common Stock Issuance
42.00
0.00
—
—
Issuance Of Capital Stock
42.00
+2539.85%
1.59
-76.40%
6.74
-20.45%
8.47
Net Preferred Stock Issuance
0.00
-100.00%
1.59
-76.40%
6.74
-20.45%
8.47
Preferred Stock Issuance
0.00
-100.00%
1.59
-76.40%
6.74
-20.45%
8.47
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category